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Despite significant improvements over the last two decades in the acute management of patients 
presenting with acute coronary syndromes (ACS) with the widespread adoption of primary 
percutaneous coronary intervention, long-term management remains challenging(1). The 
morbidity burden after ACS is high, as around 20% of survivors experience a subsequent 
cardiovascular event (recurrent myocardial infarction, stroke or cardiovascular death) during the 
first 24 months (2) and total mortality rates vary between 19- 22% by 5 years of follow-up (3). 
Residual cardiovascular risk and high rates of recurrent events generally lead to poor long-term 
prognosis (4).  
 
Thus, adequate secondary prevention after ACS is crucial in order to prevent further 
cardiovascular events, disease progression and death, and to improve length and quality of life. 
Current European guidelines recommend long-term secondary prevention through optimised 
pharmacological treatments with anti-thrombotic drugs, beta-blockers, lipid-lowering therapy, 
renin-angiotensin system inhibitors, and comprehensive lifestyle interventions with risk factor 
management and cardiac rehabilitation (5)(6). 
 
Since adherence to long-term evidence-based therapies among cardiovascular patients is 
generally poor (7), implementation of innovative strategies, multidisciplinary approaches that 
may enhance adherence and identification of patients with high risk of  non-adherence should be 
a priority (8). When investigating the persistence with secondary prevention medication in the 
TRANSLATE-ACS study (prospective observational multicenter study), nearly one-third of the 
7955 patients discontinued the prescribed medication by 6 months after ACS (9).  
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In this issue of the journal, Frederiksen et al. (10) report their findings from a large, nationwide 
population-based study, which assessed ethnic differences in the use of preventive 
pharmacological treatment and non-pharmacological interventions among survivors of ACS by 
comparing migrants and to Danish-born citizens. From the Danish national registries, they 
identified 33199 patients, who were discharged from hospital following ACS during 2010-2014, 
and examined the initiation rates and time to discontinuation of secondary preventive 
medications, in addition to participation in cardiac rehabilitation programs, determined by 
number of contacts for the interventions during a 180-days follow-up.  They found significantly 
lower initiation rates of both pharmaceutical treatment and lifestyle interventions in non-Western 
migrants (Turks and Pakistanis) compared to Danish-born citizens, whereas Western migrants 
did not differ significantly from those Danish-born. The risk of therapy discontinuation was 
found to be significantly higher for all medication groups in non-Western migrants compared to 
those Danish-born. For non-pharmacological interventions, all migrant subgroups showed 
statistically lower participation. 
 
The study by Frederiksen et al. has many positive aspects, including a large cohort size, 
statistical power and a comprehensive assessment on the use of both pharmacological and 
lifestyle changing interventional measures. Their findings are some of the first European real-
world data on treatment adherence and persistence with secondary prevention post-ACS among 
migrants, shifting the focus on the causative factors and possible interventional strategies that 
may enhance patient adherence. Nevertheless, as with most observational studies based on 
administrative data, there are several limitations that should be recognized (11).  For example, 
there are no data about follow-up visits or monitoring; no evidence about post-discharge 
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evolution of the disease or treatment-associated complications; new-onset disease(s) which may 
explain possible contraindications to secondary prevention treatment; no information about 
patient education and psychological adaptation; or bias and residual confounders from 
comorbidities. 
 
These finding serve as a reminder that due to mass immigration and significant demographic 
changes in populations, healthcare systems throughout Europe need to adapt and some ethnic 
groups may require closer attention and/or specific interventions for both primary and secondary 
prevention of ACS. The reasons for the differences in treatment initiation and persistence, and 
participation in non-pharmacological interventions, requires further exploration. It is not possible 
to ascertain from the nationwide registries if migrants were less likely to be prescribed non-
pharmacological lifestyle interventions due to physician-perceived barriers or patient refusal. In 
the present study (10) Non-Western migrants had less formal education compared to Danish-
born citizens and this, along with possible language barriers and socioeconomic factors (i.e., 
availability of disposable income to participate in required lifestyle changes, healthier food 
options, access to leisure/exercise facilities, ability to take time off work to attend cardiac 
rehabilitation (non-Western migrants were of working age), financial contribution to medication 
(as only part-coverage, etc.) may have contributed to the lower rates of initiation and adherence 
to secondary prevention among non-Western migrants. Language barriers significantly impair 
the ability of healthcare professionals to impart patient education and explain the necessity of 
medication and lifestyle change to patients. Understanding the reasons for the reported 
differences is important to target interventions appropriately; it may be more beneficial to target 
public health interventions, for primary and secondary prevention, at the whole Danish 
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population rather than focusing resources specifically on one group (migrants) but it may be that 
group-specific interventions are required.  
 
In contrast, real-world data about adherence and persistence to treatments in other chronic 
conditions, such as oral anticoagulation for stroke prevention in atrial fibrillation (AF), are more 
variable. High early vitamin K antagonist (VKA) discontinuation rates in some vulnerable 
patient groups (e.g. elderly, cardiovascular and malignant comorbidities, renal failure) still 
remain an area of concern, as cessation has been associated with poor clinical outcomes (12). In 
the era of non-vitamin K oral anticoagulants (NOACs), guideline adherence has improved 
significantly leading to higher therapy persistence with NOACs than VKA, when compared in a 
large British cohort of anticoagulation-naïve patients with non-valvular AF (13). Thus, 
emphasises the importance of patient education and proposes a well-structured follow-up system, 
which may serve as a practical model for implementation of, and to, improve cardiovascular 
treatment adherence in other fields (14).  
 
For future considerations, it is essential to identify health-system related difficulties and 
weaknesses in the management and support of secondary prevention post-ACS discharge, but 
also socioeconomic- and patient-related factors including education level, language barriers, 
immigrant status, financial concerns should be taken into consideration to optimise treatment 
adherence [Figure]. Proper utilization and adherence to evidence-based treatment strategies and 
interventions has to be the priority after acute coronary syndromes in order to improve long-term 
outcomes.  
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Figure 1. Strategies to improve patients’ treatment adherence and persistence 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
- Guideline adherence 
- Simplification of regimens , e.g. polypill 
- Continous follow-up and monitoring of adherence 
- Multiprofessional collaborations: pharmacists, clinicians, general practitioners 
- Behavioral and motivational interventions  
-Interventions to measure adherence- electronic telehomecare, memory aids, 
    reminders, feedback questionnaires 
- Good doctor-patient relationship and communication 
- Training in education and support of patients 
Improved treatment 
adherence and persistence 
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